null

null

null

null

0.05x Total Debt / Equity (Conservative)

Minimal debt leverage; cash-funded clinical-stage biotech. 200bps rate rise modestly increases opportunity cost on ~$100M cash reserves but no material debt service impact.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Chinese API/raw material suppliers for research reagents; 2) Single-source biologics CMOs (likely U.S./EU) vulnerable to regulatory shutdown or capacity constraints.

Effectively no international revenue; pre-commercial stage. Currency devaluation risk is negligible currently but will emerge upon EU/APAC commercialization.

Operations concentrated in Wilmington, MA (U.S.); no material international revenue exposure; sovereign currency devaluation risk is near-zero at current stage.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or dual contract manufacturing organizations (CMOs) for NC410/NC318 biologics production; likely >30% of operational input cost non-substitutable short-term.

Clinical-stage biopharmaceutical R&D; if cloud provider terminates, trial data management and bioinformatics pipelines face 30–90 day disruption risk requiring emergency migration.

Potential future royalty/licensing model upon commercialization; cloud termination impact on partnering data rooms and regulatory submissions would be operationally significant.

Moderate API coupling risk; bioinformatics platforms and clinical data systems (e.g., Medidata, Veeva) create switching friction but are industry-standard with migration pathways.

Low Howey Test risk; equity-funded R&D biotech with no token, royalty certificate, or investment contract revenue model triggering SEC securities classification concerns.

Very High

Low current GDPR/CCPA exposure; clinical trial patient data governed by ICH-GCP and HIPAA. EU trial expansion will require GDPR Article 9 compliance for health data.

Minimal antitrust risk; early-stage single-asset immuno-oncology company with no market share, no pricing power, and no distribution dominance in any therapeutic category.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~0% recurring revenue; 100% transactional/non-recurring (grant income, potential milestones). Pre-commercial with no product sales; entirely dependent on capital raises and partnerships.

Future monetization via drug sales (royalties/net sales), partnership milestones, and licensing fees for NC410/NC318 immuno-oncology assets; no current commercial revenue.

No commercial pricing architecture yet; future oncology biologics pricing likely $100K–$300K/year per patient based on comparable checkpoint inhibitor benchmarks.

Potential high pricing power if clinical differentiation proven; oncology biologics command premium pricing with payer reimbursement support, but unproven efficacy limits current rating.

Target gross margin 75–85% at commercial scale, typical for biologics with established CMO relationships; currently 0% gross margin as pre-revenue clinical stage.

No free-rider leakage problem applicable; no commercial product or SaaS offering. Patient/trial retention risk exists in clinical programs but is a different construct.

Revenue growth will be highly sublinear to headcount post-commercialization; biologics sales force scales modestly vs. revenue. Current R&D headcount (~50–80) is largely fixed cost.

Marginal cost of growth is capital-intensive pre-commercialization (clinical trials); post-approval, incremental revenue from existing assets requires minimal additional headcount.

Not applicable; NextCure operates no franchise network.

At 10x scale (commercial launch), CAC equivalent is oncologist/KOL medical education spend; estimated $15K–$40K per prescriber, standard for specialty oncology biologics.

No meaningful network effects; therapeutic efficacy and clinical data quality drive adoption, not user-base size. Pipeline value is asset-specific, not network-dependent.

AI displacement risk low-to-moderate; AI can accelerate target identification and trial design but cannot replace regulatory approval pathway or clinical validation of NC410/NC318.

Moderate-high recession resistance post-commercialization; oncology treatments are non-discretionary. Current risk is funding access—recession tightens biotech capital markets significantly.

Future primary customers: oncologists/hematologists at academic cancer centers and community oncology practices treating solid tumor and hematologic malignancy patients.

Secondary customers: hospital pharmacy and therapeutics committees, integrated delivery networks (IDNs), and government/commercial payers determining formulary reimbursement.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

2.1% CapEx / Revenue (Low-CapEx Asset-Light)

0001661059

NXTC